Genor Biopharma Holdings Limited

Genor Biopharma Holdings Limited a biopharmaceutical company focuses on developing and commercializing oncology and autoimmune drugs in China and internationally The companys principal drug candidates include GB242 an infliximab Remicade biosimilar for the treatment of rheumatoid arthritis ankylosing spondylitis psoriasis adult ulcerative colitis adult and pediatric crohns disease and fistulising crohns disease GB491 lerociclib an oral CDK46 inhibitor for treating hormone receptorpositive HRHER2 breast cancer and is under Phase III clinical trials and GB492 a stimulator of interferon genes STING agonist expected to exert synergistic effects in combination with GB226 for solid tumors and is under Phase 12 clinical trial Further it develops GB221 a herceptin trastuzumabmimic HER2 monoclonal antibody mAb drug candidate geptanolimab GB226 a novel PD1 mAb drug candidate GB223 a receptor activator of nuclear factorB Ligand RANKL mAb drug candidate which is under Phase I clinical trial and GB261 to treat Bcell nonHodgkin Lymphoma and is under Phase I Clinical trials In addition the companys product candidates under clinical trials include GB262 GB264 GB265 and GB 266 for the treatment of cancer Genor Biopharma Holdings Limited was formerly known as JHBP CY Holdings Limited and changed its name to Genor Biopharma Holdings Limited in June 2021 The company was founded in 2007 and is headquartered in Shanghai China